Ned Pagliarulo
BioPharma Dive
Washington, DC, United States
Contact Ned
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Ned:
Large study of J&J’s HIV vaccine stopped after shot found ineffective
The result from the nearly 4,000-person trial is the latest setback in a long-running effort to develop a safe and effective shot for HIV infections. → Read More
Vaccine factories churn out millions more doses, speeding US rollout of coronavirus shots
Initially, making one batch of Pfizer's vaccine took roughly 110 days, a timeline the company has now worked down to an average of 60 days. → Read More
Pfizer set to double weekly production of coronavirus vaccine
The drugmaker will expand its production network and work to reduce manufacturing timelines from 110 days to an average of 60 days. → Read More
US secures 200 million more vaccine doses from Pfizer, Moderna
With the orders now finalized, President Biden said the U.S. would have enough doses to vaccinate 300 million Americans by the end of the July. → Read More
New coronavirus vaccine data back up Pfizer, BioNTech claims of strongly effective shot
Reaching the main goal of their large trial, Pfizer and BioNTech reported 162 cases of COVID-19 among participants who received a placebo, and just 8 for those who were vaccinated. → Read More
US taps camera makers to manufacture drugs, coronavirus vaccines
The Trump administration will loan Kodak $765 million to produce drug ingredients, after enlisting Fujifilm to help make coronavirus vaccines, in an effort to reshore pharma supply chains. → Read More
FDA reports first drug shortage due to coronavirus impact
Supplies of the drug, which the FDA did not identify, ran short as a result of issues at a site that produces the active ingredient. Other options are available, the agency said. → Read More
Antiviral drugmakers GSK, Gilead join fight against coronavirus' spread
Gilead will work with Chinese authorities to test its drug remdesivir in a randomized study, while GSK is providing its adjuvant platforms to groups partnered with CEPI. → Read More
Sanofi's story needs to be 'better told,' new CEO says
Paul Hudson, who took over from Olivier Brandicourt as company chief a month ago, is preparing to lay out his strategy for the French drugmaker. → Read More
States pull back curtain on drug prices, to uncertain effect
A newly enacted law in Colorado requires pharma companies inform doctors of drug list prices, as well as the names of three generics in the same treatment class. → Read More
Oklahoma judge orders J&J pay $572M in landmark opioid case
"We ask the judge to ensure that needed funds are directed to the hospitals and health systems that are on the forefront of caring for the victims of this epidemic," AHA said in a joint statement with the Oklahoma Hospital Association. → Read More
Medicare boosts CAR-T cancer therapies with expanded coverage
CMS also broadened the settings in which the pricey therapies would be covered, applying its final rule to use in "healthcare facilities" rather than explicitly in hospitals. → Read More
Pharma, late to digital game, rushes to catch up
In the last two years, six of the largest pharmas appointed chief digital or information officers to top management for the first time, a signal of growing industry interest in revamping how it does business. → Read More
Drugmakers will soon be required to disclose prices in TV ads
Forcing pharma's hand, the Trump administration finalized a proposal requiring list prices in direct-to-consumer advertising, a move that could result in a legal challenge from industry. → Read More
Pharma's day in Congress: 'A hearing not a show'
Lawmakers indicated PBMs should be ready for scrutiny as well, with Sen. Ron Wyden, D-Ore., ranking member of the Finance Committee, saying they "are going to have their day in front of the committee, too." → Read More
J&J's esketamine wins backing of key advisory panel
Committee experts recommended the FDA approve the depression drug, giving cover for the agency to take a more flexible approach in its review. → Read More
Pfizer tests Trump with plans to hike prices on 41 drugs
Last month, Pfizer CEO Ian Read indicated the pharma would soon return to "business as normal" after a rare reversal on price hikes made in July. → Read More
5 election takeaways for pharma
Democrats took back the House on Tuesday, raising the prospect of more scrutiny on drug pricing. Experts, however, don't expect a major deal with President Trump. → Read More
Trump pitches new plan to bring US drug prices down
The administration's latest effort will take aim at Medicare Part B, looking to link drug payments in the U.S. to the prices pharmaceutical companies set abroad. → Read More
Viagra no more: The changing face of drug ads on TV
Gone are twin bathtubs and little blue pills. Instead, pharma promotions on TV are more likely to feature complex biologics and cancer drugs. → Read More